Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.48 |
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164774 | 0.82 | TTK (0.55) | EGLN2ARTTKCYP17A1PSMB8 | |
| SCHEMBL27669003 | 0.81 | EGLN2 (0.62) | EGLN2ARTTKCYP17A1PSMB8 | |
| SCHEMBL1438634 | 0.78 | EGLN2 (0.58) | EGLN2ARTTKTRPA1 | |
| SCHEMBL14087515 | 0.76 | ALDH1A1 (0.55) | EGLN2ARTTKCYP17A1TRPA1 | |
| SCHEMBL13244157 | 0.76 | GRM4 (0.51) | EGLN2ARTTKCYP17A1TRPA1 | |
| SCHEMBL30264004 | 0.76 | TRPA1 (0.48) | EGLN2ARTTKTRPA1MAPKAPK2 | |
| SCHEMBL31219250 | 0.76 | GRM4 (0.51) | EGLN2ARTTKCYP17A1TRPA1 | |
| SCHEMBL20865536 | 0.75 | CYP17A1 (0.68) | CYP17A1PSMB8BRD4CREBBPMAP4K4 | |
| SCHEMBL20370284 | 0.74 | CYP17A1 (0.53) | CYP17A1PSMB8BRD4CREBBPMAPKAPK2 | |
| SCHEMBL959690 | 0.74 | EGLN2 (0.55) | EGLN2CYP17A1PSMB8NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517902-B2 | Substituted indazoles, compositions containing the same, and the preparation and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | AVENTIS PHARMA S.A. (FR) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161626-A1 | Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof | CYP3A43, CYP3A7, CYP3A5 | EGLN2 1097/4885AR 2324/4885TTK 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.